PTC gains almost 10% in first day post-IPO
This article was originally published in Scrip
Executive Summary
PTC Therapeutics's lead asset ataluren targets a rare disease market with intense competition and potentially more efficacious drugs, but the company was able to price its initial public offering at $15 per share on 19 June and rise another 9.9% by the end of its first day of trading.